<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059106</url>
  </required_header>
  <id_info>
    <org_study_id>FUES02</org_study_id>
    <nct_id>NCT05059106</nct_id>
  </id_info>
  <brief_title>EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19</brief_title>
  <official_title>EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Espirito Santo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto René Rachou/Fiocruz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Escola Nacional de Saúde Pública Sérgio Arouca/Fiocruz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Programa de Computação Científica/Fiocruz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Espirito Santo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is clinical trial (intervention study with external comparison group) to test&#xD;
      vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule&#xD;
      with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city -&#xD;
      Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment,&#xD;
      compared to an external group from same state and adjusted for socio-demographic and&#xD;
      epidemiological variables.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is clinical trial (intervention study with external comparison group) to test&#xD;
      vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule&#xD;
      with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city -&#xD;
      Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment,&#xD;
      compared to an external group from same state and adjusted for socio-demographic and&#xD;
      epidemiological variables. Cellular and humoral immunity will be studied in a representative&#xD;
      sub-sample compared to an external reference group (cohort of health workers) vaccinated with&#xD;
      standard dose. The outcomes will be evaluated at 28 days after the second dose and follow-up&#xD;
      after 6 months and 12 months. The main outcome will be to decrease in 60% the incidence of&#xD;
      new cases over 6 months after receiving the vaccine. The clinical epidemiological variables&#xD;
      will be obtained from e-SUS VS, e-SUS notifica and datasus: number of cases, number of deaths&#xD;
      with specific ICD for covid-19, number of hospital admissions for covid-19; number of ICU&#xD;
      admissions for the treatment of SARS, total number of tests (RT-PCR) performed and positive.&#xD;
      The cellular and humoral immune response will be assessed by viral neutralization assay&#xD;
      (neutralizing antibody test), serological assay by chemiluminescence, determination of&#xD;
      specific IgM and IgG profiles, measurement of systemic soluble factors (chemokines, cytokines&#xD;
      and growth factors), stimulation antigen-specific peripheral blood mononuclear cells in vitro&#xD;
      and investigation of memory T and B lymphocytes and intracytoplasmic cytokines. It is&#xD;
      estimated to include 29,637 people in the study, to reach 85% vaccination cover of&#xD;
      individuals aged 18-49 years. The subsample size immunogenicity test is 600 individuals from&#xD;
      the eligible population, estimating losses of 15% and study power of 90%, alpha error of 1%.&#xD;
      The hypothesis of the study is that the reduction in the incidence of covid-19 and the&#xD;
      cellular and humoral immune response achieved with a half dose will be similar to the&#xD;
      reduction expected with the standard dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of new cases</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of new cases over 12 months following treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>12 months</time_frame>
    <description>Number of deaths with specific ICD for covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospital admissions</measure>
    <time_frame>12 months</time_frame>
    <description>number of hospital admissions for covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of intensive care unit (ICU) admissions</measure>
    <time_frame>12 months</time_frame>
    <description>number of intensive care unit (ICU) admissions for the treatment of SARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of tests (RT-PCR)</measure>
    <time_frame>12 months</time_frame>
    <description>number of tests (RT-PCR) performed and positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Neutralization Assay</measure>
    <time_frame>4 and 8 months</time_frame>
    <description>Neutralizing antibody titers will be expressed by the ability of antibodies to neutralize up to 50% the number of plaques (PRNT50). Title &gt; 1:50 will be considered positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serological assay</measure>
    <time_frame>8 and 10 months</time_frame>
    <description>Serological test by chemiluminescence. Results are expressed in U/mL and data interpretation will be done as follows: &lt;0.8 U/mL = non-reactive sample; ≥0.8 U/mL = reactive sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgM</measure>
    <time_frame>8 and 10 months</time_frame>
    <description>Determination of specific IgM profile. Results will be expressed in fluorescence intensity or pg/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG</measure>
    <time_frame>8 and 10 months</time_frame>
    <description>Determination of specific IgG profile. Results will be expressed in fluorescence intensity or pg/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic soluble factors</measure>
    <time_frame>8 and 10 months</time_frame>
    <description>Dosage of soluble systemic factors (chemokines, cytokines and growth factors). Results will be expressed in pg/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigen-specific stimulation of peripheral blood mononuclear cells</measure>
    <time_frame>10 and 12 months</time_frame>
    <description>Antigen-specific stimulation of peripheral blood mononuclear cells in vitro. The results will be expressed in percentage positive frequency for a specific cell phenotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte investigation</measure>
    <time_frame>10 and 12 months</time_frame>
    <description>Investigation of memory T and B lymphocytes. The results will be expressed in percentage positive frequency for a specific cell phenotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine investigation</measure>
    <time_frame>10 and 12 months</time_frame>
    <description>Investigation of intracytoplasmic cytokines. The results will be expressed in percentage positive frequency for a specific cell phenotype.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>14 months</time_frame>
    <description>All adverse events will be followed up to establish severity and causal correlation. There will be surveillance of deaths and will be reported to the ethics committee.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">29637</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half dose of ChAdOx1 nCoV-19 (AZD1222) ) in a 2-dose schedule with an interval of 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standad dose of ChAdOx1 nCoV-19 (AZD1222) in a 2-dose schedule with an interval of 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Half dose of ChAdOx1 nCoV-19 (AZD1222)</intervention_name>
    <description>Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard dose of ChAdOx1 nCoV-19 (AZD1222)</intervention_name>
    <description>Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - residents of Viana, Espírito Santo, aged between 18 and 49 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women;&#xD;
&#xD;
          -  History of severe allergic reaction (anaphylaxis) to any previously administered&#xD;
             vaccine;&#xD;
&#xD;
          -  Having received another vaccine in the last 14 days;&#xD;
&#xD;
          -  Belonging to a priority risk group for vaccination, as per the PNI recommendations;&#xD;
&#xD;
          -  Have fever or flu-like symptoms;&#xD;
&#xD;
          -  Have previously received any vaccine for covid-19 at any time;&#xD;
&#xD;
          -  Recent diagnosis of covid-19 with onset of symptoms 28 days before vaccination;&#xD;
&#xD;
          -  Disorders of coagulation and use of anticoagulants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valéria Valim, PhD</last_name>
    <phone>+5527999874665</phone>
    <email>val.valim@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal University of Espirito Santo</name>
      <address>
        <city>Vitória</city>
        <state>Espirito Santo</state>
        <zip>29041-295</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valéria Valim, PhD</last_name>
      <phone>+55 27 99987-4665</phone>
      <email>val.valim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>José G Mill, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olindo A Martins Filho, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andréa T Carvalho, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luiz AB Camacho, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel AM Vilela, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauro Pinto Neto, 'PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Espirito Santo</investigator_affiliation>
    <investigator_full_name>Valéria Valim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>vaccines</keyword>
  <keyword>immunity</keyword>
  <keyword>covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

